Core Viewpoint - The article highlights the transformation of Panzhihua, a city in Sichuan, from a historically industrial town to a leading economic area, driven by its rich vanadium-titanium resources and strategic investments in industrial development [6][7][9]. Group 1: Panzhihua's Economic Transformation - Panzhihua has become the city with the highest per capita GDP in Sichuan, challenging previous stereotypes of being remote and underdeveloped [6]. - The city is recognized as the only city-level common prosperity pilot zone in the country, addressing common challenges faced by resource-based industrial cities [9]. - A significant investment of 5 billion RMB was made to establish a vanadium-titanium industry development fund, marking a strategic move to promote industrial growth [8]. Group 2: New Fund Establishments - A new venture capital partnership was established in Shanghai with a total investment of 2.75 billion RMB, involving major players like Jianxin Investment and SAIC [12]. - The establishment of the "Beijing Shouchang Future Intelligent Manufacturing Industry Fund" with a capital of 200 million RMB aims to support private equity investment and venture capital management [14]. - The "Dehua County Industry Guidance Mother Fund" has been approved with a total scale of 2 billion RMB, focusing on various sub-funds to enhance local industrial development [17]. Group 3: Sector-Specific Funds - The "Guangxi Yuchai Doubling Phase I Industry Development Fund" has been established with a total scale of 1 billion RMB, focusing on the core diesel engine industry chain [25]. - The "Hubei Hongtai New Industry Investment Fund" has been set up with a total scale of 1 billion RMB, targeting strategic emerging industries in Hubei [23]. - The "Anhui Pet Industry Fund" has launched with an initial scale of 200 million RMB, focusing on various segments of the pet industry, aiming for a market scale of over 5 billion RMB by 2027 [18].

Investment Rating - The industry investment rating for the medical biology sector is "Hold" [2]. Core Insights - The report highlights significant advancements in the brain-computer interface (BCI) industry, emphasizing the acceleration of industrial development and the establishment of a robust innovation ecosystem [3][4]. - The Shanghai Municipal Government has released a plan to cultivate the BCI industry, aiming for clinical applications of semi-invasive and invasive BCI products by 2027, with a comprehensive application by 2030 [4]. - The report suggests that the BCI field is entering a rapid development phase, driven by the release of industry standards and supportive government policies [7]. Summary by Sections Industry Overview - The BCI industry is experiencing accelerated industrialization, with recent breakthroughs in invasive devices and the establishment of new treatment paradigms for conditions like epilepsy [4][6]. - The report notes the importance of integrating BCI technology with artificial intelligence and virtual reality to enhance product offerings and market reach [4]. Government Initiatives - The Shanghai action plan outlines key milestones, including the development of over five invasive and semi-invasive BCI products for clinical trials and the establishment of a national-level BCI industry development zone [4]. - The plan also emphasizes the need for collaboration between innovative entities and medical institutions to foster product development in various applications, including rehabilitation and education [4]. Investment Recommendations - The report recommends focusing on companies such as Innovation Medical, Aipeng Medical, and Sanbo Brain Science, which are positioned to benefit from the growing BCI market [7].

北京市中伦律师事务所 关于三博脑科医院管理集团股份有限公司 2026 年第一次临时股东会的 法律意见 二〇二六年一月 北京 • 上海 • 深圳 • 广州 • 武汉 • 成都 • 重庆 • 青岛 • 杭州 • 南京 • 海口 • 东京 • 香港 • 伦敦 • 纽约 • 洛杉矶 • 旧金山 • 阿拉木图 Beijing • Shanghai • Shenzhen • Guangzhou • Wuhan • Chengdu • Chongqing • Qingdao • Hangzhou • Nanjing • Haikou • Tokyo • Hong Kong • London • New York • Los Angeles • San Francisco • Almaty 北京市中伦律师事务所 关于三博脑科医院管理集团股份有限公司 2026 年第一次临时股东会的 法律意见 致：三博脑科医院管理集团股份有限公司 北京市中伦律师事务所（以下简称"本所"）接受三博脑科医院管理集团股份 有限公司（以下简称"公司"）委托，指派本所律师列席公司 2026 年第一次临时 股东会（以下简称"本次股东会"），并出具本法律意见 ...

特别提示： 三博脑科医院管理集团股份有限公司 2026 年第一次临时股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 证券代码：301293 证券简称：三博脑科 公告编号：2026-003 1、本次股东会未出现否决议案的情形； 2、本次股东会未涉及变更以往股东会已通过的决议。 一、会议召开和出席情况 2、会议召开的合法、合规性：本次股东会的召开符合有关法律、行政法规、 部门规章、规范性文件及《公司章程》的规定。 3、会议召开时间： （1）现场会议时间：2026 年 1 月 16 日下午 15:30 （2）网络投票时间：通过深圳证券交易所交易系统进行网络投票的具体时 间为：2026 年 1 月 16 日上午 9:15-9:25、9:30-11:30，下午 13:00-15:00；通过深 圳证券交易所互联网投票系统投票的具体时间为：2026 年 1 月 16 日 9:15-15:00 期间的任意时间。 4、会议召开方式：现场投票与网络投票相结合的方式。 5、现场会议召开地点：北京市海淀区世纪金源香山商旅酒店 831 栋公司会 议室 （一）会议召开情况 ...

Core Insights - The announcement by Elon Musk regarding Neuralink's plans for large-scale production and fully automated surgeries in 2026 marks a significant step towards the commercialization of brain-machine interfaces (BMIs) [1][2] - The excitement in global capital markets is evident, with related stocks in the A-share market experiencing significant gains, indicating a strong investor interest in the BMI sector [2] Group 1: Technological Advancements - Neuralink is leading the invasive BMI sector by integrating AI into the entire process, significantly reducing surgery time from 6-8 hours to approximately 30 minutes, which is described as a "production line" approach [3][4] - The R1 surgical robot developed by Neuralink utilizes AI for real-time navigation, achieving micro-level precision in electrode placement, thus minimizing surgical trauma [3] - Neuralink's devices can decode neural signals with over 95% accuracy, allowing paralyzed individuals to perform tasks like gaming and social media interaction using only their thoughts [4] Group 2: Competitive Landscape - Chinese companies are exploring different technical routes in the BMI space, with firms like Boryeong and BrainTiger focusing on semi-invasive and flexible electrode technologies to balance signal quality and safety [5][6] - Boryeong's NEO system has successfully completed surgeries on 36 spinal injury patients, demonstrating the potential for restoring motor functions [5] - BrainTiger has made strides in real-time Chinese language decoding, achieving a 71.5% accuracy rate in clinical trials, showcasing advanced capabilities in high-level brain function decoding [6] Group 3: Market Challenges - Despite the technological advancements, the BMI industry faces significant hurdles in transitioning from innovative technology to a mature business model, with current clinical trials being limited in scope [7][8] - The market for BMIs is highly specialized, targeting severe neurological conditions, which may limit its immediate commercial viability [8] - The long-term reliability of implanted devices is a concern, as immune responses can lead to signal degradation, posing challenges for sustained use [9] Group 4: Ethical and Regulatory Considerations - The collection and use of neural data raise ethical questions regarding privacy and data security, with a lack of established regulations in place [10][11] - The potential for misuse of technology and risks associated with hacking highlight the need for a robust ethical framework to guide the commercialization of BMIs [10][11] - The balance between investor enthusiasm and the practical realities of the BMI market will be crucial for the industry's future [11]

格隆汇1月16日｜今日医疗设备板块走势震荡，截至发稿，医疗设备ETF(159873)成交额4859.76万元， 换手率超26%，在同标的产品中处断层第一，且盘中获资金净申购5700万份，此前6日连续获资金净流 入，累计"吸金"超6000万元，近10日净流率60%。芯片板块强势上涨，带动芯片ETF天弘(159310）标的 指数上涨3.08%。 消息面上: ①台积电第四季度财报及展望远超过预期，清晰释放出人工智能热潮将持续的信号。台积电第四季度净 利润同比大幅增长35%，创下历史新高，且2026年资本支出计划最高将达560亿美元，较2025年大幅增 长37%，创下该公司的史上新高。 ③翔宇医疗预计2026年有5-6款AI理疗机器人系列产品陆续下证。 同标的规模第一的医疗设备ETF（159873）跟踪医疗保健指数，脑机接口含量较高，占比超17%！科技 属性强，成分股中科创版+创业板含量占比近80%。在国产创新替代、出口加速及新技术加持下，有望 迎来全面估值修复。其覆盖三博脑科、翔宇医疗、伟思医疗等脑机接口核心概念。 芯片ETF天弘(159310）跟踪中证芯片产业指数，覆盖芯片设计、制造、封装测试等核心环节，直接受 ...

Group 1 - The medical device sector is experiencing volatility, with the medical device ETF (159873) achieving a trading volume of 48.6 million yuan and a turnover rate exceeding 26%, leading in its category [1] - The medical device ETF has seen a net inflow of over 60 million yuan in the past 10 days, with a net subscription of 57 million units in the latest session [1] - TSMC's fourth-quarter earnings report exceeded expectations, with a net profit growth of 35% year-on-year, signaling a sustained AI boom [1] Group 2 - The medical device ETF (159873) tracks the healthcare index and has a high concentration of brain-computer interface stocks, accounting for over 17% of its holdings [2] - The ETF includes significant exposure to innovative domestic companies and is expected to undergo a comprehensive valuation recovery due to accelerated exports and new technologies [2] - The chip ETF Tianhong (159310) tracks the semiconductor industry index and benefits directly from domestic substitution and technological breakthroughs in the semiconductor sector [2]

（文章来源：证券日报） 证券日报网讯 1月15日，三博脑科在互动平台回答投资者提问时表示，目前公司财务部门正在核算2025 年度的财务数据，如触及披露标准，公司将按规定在指定媒体公开披露，请留意公司的公告。 ...

Core Viewpoint - Sanbo Brain Science (301293.SZ) is making progress in its brain-computer interface (BCI) business, but its main revenue still comes from high-end neurosurgery services, with BCI technology currently contributing minimally to overall performance [2]. Group 1: Surgical Trials - The company has completed one interventional brain-computer interface surgery at its Fujian branch, with no other surgeries reported within the group [2]. Group 2: External Investment and Collaboration - Sanbo Brain Science has previously invested in three brain science funds and has established a joint research center for precision medicine in collaboration with Tsinghua University’s School of Biomedical Engineering [2]. - Ongoing projects related to these collaborations are still in progress [2]. Group 3: Revenue Impact - The revenue generated from the company's neuromodulation technology is currently very small, having a negligible impact on the company's overall performance [2].

Core Viewpoint - Sanbo Neuroscience (301293.SZ) is a medical service group specializing in neurology, primarily providing advanced neurosurgical services, with current revenue from neuromodulation technology being minimal and not significantly impacting overall performance [1] Company Overview - The company operates as a specialized medical service group focused on neurology [1] - Its main facilities offer comprehensive medical services centered around high-end neurosurgery [1] Revenue Insights - Revenue generated from neuromodulation technology constitutes a small portion of the company's total revenue [1] - The impact of this revenue stream on the company's overall performance is negligible [1]